Advertisement

Pre-exposure Prophylaxis Among Men Who have Sex with Men: Dual Motivational Model of Intention to Use Pre-exposure Prophylaxis

  • Yerina S. Ranjit
  • Alex Dubov
  • Maxim Polonsky
  • Liana Fraenkel
  • Adedotun Ogunbajo
  • Kenneth Mayer
  • Frederick L. Altice
Original Paper

Abstract

Men who have sex with men (MSM) account for most new HIV infections in the United States. Despite representing a fraction of the population, MSM make up an estimated 65% of new infections. To address this epidemic, pre-exposure prophylaxis (PrEP) is recommended to supplement condom use. Despite its effectiveness, PrEP uptake among MSM is low. Few studies have employed theoretical approaches to understand PrEP use intention. Incorporating factors like safe sex fatigue, expectation of better sexual experiences, and perceived risk are proposed in this dual motivational path model of PrEP use intention. This model hypothesized that PrEP use intention is influenced by two key pathways: (1) protection motivation pathway, and (2) sexual expectancy pathway. Data were collected using social networking applications from 402 MSM. The model was tested using structural equation modeling. We elaborate the complex decision-making process proposed by this novel theoretical model and discuss its practical implications.

Keywords

Men who have sex with men (MSM) Pre-exposure prophylaxis (PrEP) Dual motivational model Safe sex fatigue, perceived risk 

Notes

Funding

Research reported in this publication was supported by the National Institute of Arthritis and Musculoskeletal and Skin Diseases, part of the National Institutes of Health, under Award Number AR060231-06 (Fraenkel). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors do not have any conflicts of interest related to the content of this manuscript.

Compliance with Ethical Standards

Conflict of interest

Yerina S. Ranjit, Alex Dubov, Maxim Polonksy, Liana Fraenkel, Adedotun Ogunbajo, Kenneth Mayer, and Frederick L. Altice declare that they have no conflict of interest.

Ethical Approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed Consent

Informed consent was obtained from all individual participants included in the study.

References

  1. 1.
    Linley L, An Q, Song R, Valverde E, Oster AM, Qian X, et al. HIV testing experience before HIV diagnosis among men who have sex with men—21 Jurisdictions, United States, 2007-2013. MMWR Morb Mortal Wkly Rep. 2016;65(37):999–1003.CrossRefPubMedGoogle Scholar
  2. 2.
    Wolitski RJ, Valdiserri RO, Denning PH, Levine WC. Are we headed for a resurgence of the HIV epidemic among men who have sex with men? Am J of Public Health. 2001;91(6):883–8.CrossRefGoogle Scholar
  3. 3.
    Kalichman SC. Post-exposure prophylaxis for HIV infection in gay and bisexual men: implications for the future of HIV prevention. Am J Prev Med. 1998;15(2):120–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;16(4):266–71.CrossRefPubMedGoogle Scholar
  5. 5.
    CDC. HIV testing and risk behaviors among gay, bisexual, and other men who have sex with men—United States. MMWR Morb Mortal Wkly Rep. 2013;62(47):958–62.Google Scholar
  6. 6.
    Paz-Bailey G, Mendoza MCB, Finlayson T, Wejnert C, Le B, Rose C, et al. Trends in condom use among MSM in the United States: the role of antiretroviral therapy and seroadaptive strategies. AIDS. 2016;30(12):1985–90.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Smith DK, Grant RM, Weidle PJ, Lansky A, Mermin J, Fenton KA. Interim guidance: pre-exposure prophylaxis for the prevention of HIV infection in men who have sex with men. CDC, 2011.Google Scholar
  8. 8.
    Donnell D, Baeten JM, Bumpus NN, Brantley J, Bangsberg DR, Haberer JE, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr Hum Retrovirol. 2014;66(3):340–8.CrossRefGoogle Scholar
  9. 9.
    Spinner CD, Boesecke C, Zink A, Jessen H, Stellbrink HJ, Rockstroh JK, et al. HIV pre-exposure prophylaxis (PrEP): a review of current knowledge of oral systemic HIV PrEP in humans. Infection. 2016;44(2):151–8.CrossRefPubMedGoogle Scholar
  10. 10.
    Vissers DCJ, Voeten HACM, Nagelkerke NJD, Habbema JDF, de Vlas SJ. The impact of pre-exposure prophylaxis (PrEP) on HIV epidemics in Africa and India: a simulation study. PLoS ONE. 2008;3(5):e2077.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Choopanya K, Martin M, Suntharasamai P, Sangkum U, Mock PA, Leethochawalit M, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.CrossRefPubMedGoogle Scholar
  12. 12.
    Hanscom B, Janes HE, Guarino PD, Huang Y, Brown ER, Chen YQ, et al. Brief report: preventing HIV-1 infection in women using oral preexposure prophylaxis: a meta-analysis of current evidence. J Acquir Immune Defic Syndr. 2016;73(5):606–8.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Deutsch MB, Glidden DV, Sevelius J, Keatley J, McMahan V, Guanira J, et al. HIV pre-exposure prophylaxis in transgender women: a subgroup analysis of the iPrEx trial. Lancet HIV. 2015;2(12):e512–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Krakower DS, Mimiaga MJ, Rosenberger JG, Novak DS, Mitty JA, White JM, et al. Limited awareness and low immediate uptake of pre-exposure prophylaxis among men who have sex with men using an internet social networking site. PLoS ONE. 2012;7(3):e33119.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Hood JE, Buskin SE, Dombrowski JC, Kern DA, Barash EA, Katzi DA, et al. Dramatic increase in preexposure prophylaxis use among MSM in Washington state. AIDS. 2016;30(3):515–9.PubMedGoogle Scholar
  16. 16.
    Holloway I, Dougherty R, Gildner J, Beougher SC, Pulsipher C, Montoya JA, et al. PrEP Uptake, adherence, and discontinuation among California YMSM using geosocial networking applications. J Acquir Immune Defic Syndr (1999). 2017;74(1):15–20.Google Scholar
  17. 17.
    Gomez GB, Borquez A, Caceres CF, Segura ER, Grant RM, Garnett GP, et al. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and Transwomen in Lima, Peru: a mathematical modelling study. PLoS Med. 2012;9(10):e1001323.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Mayer KH, Oldenburg CE, Novak DS, Elsesser SA, Krakower DS, Mimiaga MJ. Early adopters: correlates of HIV chemoprophylaxis use in recent online samples of US men who have sex with men. AIDS Behav. 2016;20(7):1489–98.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Golub SA, Gamarel KE, Rendina HJ, Surace A, Lelutiu-Weinberger CL. From efficacy to effectiveness: facilitators and barriers to PrEP acceptability and motivations for adherence among MSM and transgender women in New York City. AIDS Patient Care STDS. 2013;27(4):248–54.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Hoff CC, Chakravarty D, Bircher AE, Campbell CK, Grisham K, Neilands TB, et al. Attitudes towards PrEP and anticipated condom use among concordant HIV-negative and HIV-discordant male couples. AIDS Patient Care STDS. 2015;29(7):408–17.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Golub SA, Kowalczyk W, Weinberger CL, Parsons JT. Preexposure prophylaxis and predicted condom use among high-risk men who have sex with men. J Acquir Immune Defic Syndr. (1999). 2010;54(5):548–55.Google Scholar
  22. 22.
    Carlo Hojilla J, Koester KA, Cohen SE, Buchbinder S, Ladzekpo D, Matheson T, et al. Sexual behavior, risk compensation, and HIV prevention strategies among participants in the San Francisco PrEP demonstration project: a qualitative analysis of counseling notes. AIDS Behav. 2016;20(7):1461–9.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Cain M. Sex without fear: my experience with the HIV-prevention drug PrEP. The Guardian. 2017 June 22.Google Scholar
  24. 24.
    Hogben M, Liddon N. Disinhibition and risk compensation: scope, definitions, and perspective. Sex Transm Dis. 2008;35(12):1009.PubMedGoogle Scholar
  25. 25.
    Rudy BJ, Kapogiannis BG, Lally MA, Gray GE, Bekker LG, Krogstad P, et al. Youth-specific considerations in the development of preexposure prophylaxis, microbicide, and vaccine research trials. J Acquir Immune Defic Syndr. 2010;54(Suppl 1):S31–42.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Guest G, Shattuck D, Johnson L, Akumatey B, Clarke EE, Chen PL, et al. Changes in sexual risk behavior among participants in a PrEP HIV prevention trial. Sex Transm Dis. 2008;35(12):1002–8.PubMedGoogle Scholar
  27. 27.
    Eaton LA, Kalichman SC. Risk compensation in HIV prevention: implications for vaccines, microbicides, and other biomedical HIV prevention technologies. Current HIV/AIDS Rep. 2007;4(4):165–72.CrossRefGoogle Scholar
  28. 28.
    Kalichman SC, Rompa D. Sexual sensation seeking and Sexual Compulsivity Scales: reliability, validity, and predicting HIV risk behavior. J Pers Assess. 1995;65(3):586–601.CrossRefPubMedGoogle Scholar
  29. 29.
    Marcus JL, Glidden DV, Mayer KH, Liu AY, Buchbinder SP, Amico KR, et al. No evidence of sexual risk compensation in the iPrEx trial of daily oral HIV preexposure prophylaxis. PLoS ONE. 2013;8(12):e81997.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Chesney MA, Chambers DB, Kahn JO. Risk behavior for HIV infection in participants in preventive HIV vaccine trials: a cautionary note. J Acquir Immune Defic Syndr. 1997;16(4):266–71.CrossRefGoogle Scholar
  31. 31.
    Martin JN, Roland ME, Neilands TB, Krone MR, Bamberger JD, Kohn RP, et al. Use of postexposure prophylaxis against HIV infection following sexual exposure does not lead to increases in high-risk behavior. AIDS. 2004;18(5):787–92.CrossRefPubMedGoogle Scholar
  32. 32.
    Ostergren JE, Rosser BRS, Horvath KJ. Reasons for non-use of condoms among men-who-have-sex-with-men: a comparison of receptive and insertive role-in-sex and online and offline meeting venue. Cult Health Sex. 2011;13(2):123–40.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Sarkar NN. Barriers to condom use. Eur J Contracept Reprod Health Care. 2008;13(2):114–22.CrossRefPubMedGoogle Scholar
  34. 34.
    Carballo-Diéguez A, Dolezal C. HIV risk behaviors and obstacles to condom use among Puerto Rican men in New York City who have sex with men. Am J Public Health. 1996;86(11):1619–22.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Ho DD. Therapy of HIV infections: problems and prospects. Bull N Y Acad Med. 1996;73(1):37–45.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Wolitski RJ. The emergence of barebacking Among Gay and bisexual men in the United States: a public health perspective. J Gay Lesbian Psychother. 2005;9(3/4):9–34.CrossRefGoogle Scholar
  37. 37.
    Gamarel K, Golub S. Intimacy motivations and pre-exposure prophylaxis (PrEP) adoption intentions among HIV-negative men who have sex with men (MSM) in romantic relationships. Ann Behav Med. 2015;49(2):177–86.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Golub SA, Starks TJ, Payton G, Parsons JT. The critical role of intimacy in the sexual risk behaviors of gay and bisexual men. AIDS Behav. 2012;16(3):626–32.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Rowniak S. Safe sex fatigue, treatment optimism, and serosorting: new challenges to HIV prevention among men who have sex with men. J Assoc Nurses AIDS Care. 2009;20(1):31–8.CrossRefPubMedGoogle Scholar
  40. 40.
    Blackwell CW. Men who have sex with men and recruit bareback sex partners on the internet: implications for STI and HIV prevention and client education. Am J Mens Health. 2008;2(4):306–13.CrossRefPubMedGoogle Scholar
  41. 41.
    Stolte IG, de Wit JBF, Kolader M, Fennema H, Coutinho RA, Dukers NHTM. Association between ‘safer sex fatigue’ and rectal gonorrhea is mediated by unsafe sex with casual partners among HIV-positive homosexual men. Sex Transm Dis. 2006;33(4):201–8.PubMedGoogle Scholar
  42. 42.
    Kellogg AP. ‘Safe sex fatigue’ grows among gay students. Chronicle High Educ. 2002;48(19):A37.Google Scholar
  43. 43.
    Ostrow DG, Silverberg MJ, Cook RL, Chmiel JS, Johnson L, Li X, et al. Prospective study of attitudinal and relationship predictors of sexual risk in the multicenter AIDS cohort study. AIDS Behav. 2007;12(1):127.CrossRefPubMedGoogle Scholar
  44. 44.
    Coleman CL, Ball K. Determinants of perceived barriers to condom use among HIV-infected middle-aged and older African-American men. J Adv Nurs. 2007;60(4):368–76.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Balán IC, Carballo-Diéguez A, Ventuneac A, Remien RH, Dolezal C, Ford J. HIV-negative men-who-have-sex-with-men who bareback are concerned about HIV infection: implications for HIV risk reduction interventions. Arch Sex Behav. 2013;42(2):279–89.CrossRefPubMedGoogle Scholar
  46. 46.
    Aghaizu A, Mercey D, Copas A, Johnson AM, Hart G, Nardone A. Who would use PrEP? Factors associated with intention to use among MSM in London: a community survey. Sex Transm Infect. 2013;89(3):207–11.CrossRefPubMedGoogle Scholar
  47. 47.
    Mimiaga MJ, Case P, Johnson CV, Safren SA, Mayer KH. Preexposure antiretroviral prophylaxis attitudes in high-risk Boston area men who report having sex with men: limited knowledge and experience but potential for increased utilization after education. J Acquir Immune Defic Syndr. 2009;50(1):77–83.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Grov C, Rendina HJ, Jimenez R, Parsons JT. Using online settings to identify gay and bisexual men willing to take or with experience taking PrEP: implications for researchers and providers. AIDS Educ Prev. 2016;28(5):378–92.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Wade Taylor S, Mayer KH, Elsesser SM, Mimiaga MJ, O’Cleirigh C, Safren SA. Optimizing content for pre-exposure prophylaxis (PrEP) counseling for men who have sex with men: perspectives of PrEP users and high-risk PrEP Naïve men. AIDS Behav. 2014;18(5):871–9.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Rendina HJ, Whitfield THF, Grov C, Starks TJ, Parsons JT. Distinguishing hypothetical willingness from behavioral intentions to initiate HIV pre-exposure prophylaxis (PrEP): findings from a large cohort of gay and bisexual men in the U.S. Soc Sci Med. 2017;172:115–23.CrossRefPubMedGoogle Scholar
  51. 51.
    Jackson T, Huang A, Chen H, Gao X, Zhong X, Zhang Y. Cognitive, psychosocial, and sociodemographic predictors of willingness to use HIV pre-exposure prophylaxis among Chinese men who have sex with men. AIDS Behav. 2012;16(7):1853–61.CrossRefPubMedGoogle Scholar
  52. 52.
    Shrestha R, Altice FL, Huedo-Medina TB, Karki P, Copenhaver M. Willingness to use pre-exposure prophylaxis (PrEP): an empirical test of the information-motivation-behavioral skills (IMB) model among high-risk drug users in treatment. AIDS Behav. 2017;21(5):1299–308.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Helweg-Larsen M, Collins BE. The UCLA multidimensional condom attitudes scale: documenting the complex determinants of condom use in college students. Health Psychol. 1994;13(3):224–37.CrossRefPubMedGoogle Scholar
  54. 54.
    Ostrow DE, Fox KJ, Chmiel JS, Silvestre A, Visscher BR, Vanable PA, et al. Attitudes towards highly active antiretroviral therapy are associated with sexual risk taking among HIV-infected and uninfected homosexual men. AIDS. 2002;16(5):775.CrossRefPubMedGoogle Scholar
  55. 55.
    Dermen KH, Cooper ML. Sex-related alcohol expectancies among adolescents: I. Scale development. Psychol Addict Behav. 1994;8(3):152–60.CrossRefGoogle Scholar
  56. 56.
    Napper L, Fisher D, Reynolds G. Development of the perceived risk of HIV Scale. AIDS Behav. 2012;16(4):1075–83.CrossRefPubMedGoogle Scholar
  57. 57.
    Chin WW. Commentary: issues and opinion on structural equation modeling. MIS Q. 1998;22(1):vii–xvi.Google Scholar
  58. 58.
    Bollen KA, Long JS. Tests for structural equation models: introduction. Sociol Methods Res. 1992;21(2):123–31.CrossRefGoogle Scholar
  59. 59.
    Arbuckle JL. Amos. 24th ed. Chicago: IBM; 2014.Google Scholar
  60. 60.
    Barrett P. Structural equation modelling: adjudging model fit. Pers Individ Dif. 2007;42(5):815–24.CrossRefGoogle Scholar
  61. 61.
    Fairchild A, MacKinnon D. A general model for testing mediation and moderation effects. Prev Sci. 2009;10(2):87–99.CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Adam BD, Husbands W, Murray J, Maxwell J. AIDS optimism, condom fatigue, or self-esteem? Explaining unsafe sex among gay and bisexual men. J Sex Res. 2005;42(3):238–48.CrossRefPubMedGoogle Scholar
  63. 63.
    Hall HI, Frazier EL, Rhodes P, Holtgrave DR, Furlow-Parmley C, Tang T, et al. Differences in human immunodeficiency virus care and treatment among subpopulations in the United States. JAMA Intern Med. 2013;173(14):1337–44.CrossRefPubMedGoogle Scholar
  64. 64.
    Brodie M, Flournoy RE, Altman DE, Blendon RJ, Benson JM, Rosenbaum MD. Health information, the internet, and the digital divide. Health Aff. 2000;19(6):255–65.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Yerina S. Ranjit
    • 1
  • Alex Dubov
    • 2
  • Maxim Polonsky
    • 3
  • Liana Fraenkel
    • 4
  • Adedotun Ogunbajo
    • 5
  • Kenneth Mayer
    • 6
  • Frederick L. Altice
    • 1
  1. 1.AIDS Program, Department of Internal MedicineYale UniversityNew HavenUSA
  2. 2.Loma Linda University School of Public HealthLoma LindaUSA
  3. 3.Quinnipiac University School of BusinessHamdenUSA
  4. 4.Section of RheumatologyYale University School of MedicineNew HavenUSA
  5. 5.Department of Behavioral and Social SciencesBrown University School of Public HealthProvidenceUSA
  6. 6.Department of Global Health and PopulationHarvard T.H. Chan, School of Public HealthBostonUSA

Personalised recommendations